Quantifying psilocybin exposure in a natural product–based retreat setting: An observational field method for dose measurement

Background: In natural product psilocybin retreats, "dose" is commonly defined by grams of dried mushrooms, despite substantial batch-to-batch variability in psilocybin content. This limits safety predictability and undermines reproducibility and between-study comparability. We report an observational field evaluation of an existing, ICH Q2(R1)-validated rapid colorimetric/photometric assay (PSILO QTest) deployed inside routine operations of a 7-day psilocybin retreat in Jamaica; the contribution is a field-method demonstration with feasibility-level human data, not a controlled methodological inference study of dosing strategy, tolerance compensation, or safety.

Methods: We conducted a prospective, observational field evaluation of a rapid colorimetric/photometric assay (PSILO QTest with 590 nm photometer) to quantify batch-level psilocybin concentration in Psilocybe cubensis material used during routine operations of a 7-day retreat in Jamaica. Retreat participation and all clinical/safety procedures, including participant screening, batch selection, dose preparation, dose selection, and dose administration, were determined by the retreat provider; assay results were recorded for research and were not used to inform dose selection or administration. The lead facilitator was blinded to the per-batch mg/g assay values during all in-session decision-making and was informed of the measurements only after both sessions had concluded. After routine homogenization and dose preparation, two independent measurements were performed per session, each on a separate aliquot of the homogenized batch and each comprising an independent material extraction and an independent colorimetric reaction with the detection reagent, followed by photometric quantification (mg/g). Psilocybin-equivalent dose content (mg) was estimated post hoc by multiplying the per-batch concentration estimate (mean of two independent measurements) (mg/g) by the recorded dry mass allocated per participant (g) across two supervised sessions separated by ∼48 h.

Results: Estimated psilocybin concentration differed approximately 2.6-fold between the two session batches: Session 1 (1:1 Fat Mac: Cambodian) yielded a mean of 6.095 mg/g across two independent preparation replicates (range 6.08–6.11 mg/g), and Session 2 (Monster Mac) yielded a mean of 15.75 mg/g (range 15.7–15.8 mg/g). Consequently, gram-based dosing are not the most adequate approach to estimate psychoactive substance exposure: estimated psilocybin-equivalent doses ranged from 15.2 to 21.3 mg in Session 1 and 47.1–70.7 mg in Session 2. No serious adverse events were documented by the retreat provider´s team during the observation window; given the cohort size (n = 11), this is reported as an operational observation and does not support population-level claims.

Conclusions: This study demonstrates that an existing, ICH Q2(R1)-validated rapid colorimetric/photometric assay can be operationally deployed inside a live psilocybin retreat and used to generate batch-level potency estimates that translate gram-based dosing records into psilocybin-equivalent dose estimates. Field-deployable quantification of this kind, feasible for non-chemist facilitators to perform in situ, can strengthen exposure documentation in naturalistic psilocybin research and, if adopted by retreats working with whole natural-product mushrooms, could support more controlled dosing. Future work should cross-validate field assays against chromatographic reference methods on the specific batches used in a deployment and quantify real-world measurement uncertainty.